ClinicalTrials.gg
Drug

Sotorasib clinical trials

Also written AMG 510 and Lumakras.

studies test it
50
open now
17
in phase 3
4
first study started
2018

How each study uses sotorasib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the sotorasib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
28 May 2021 · LUMAKRAS · NDA 214665 (FDA, Drugs@FDA)
European Union
6 Jan 2022 · Lumykras · EMEA/H/C/005522 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Sotorasib
35
Lumykras
8
Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
2

Brand

Lumakras
8

Development codes

AMG 510
28

Studies by the year they started

50 studies that test it; most in 2022 (13)

Studies that test sotorasib, by start year
YearStudies
20181
20197
20206
20215
202213
20236
20246
20253
20263

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
29
Phase 2
22
Phase 3
4
Phase 4
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 28 · Other 22

Amgen (24) · Memorial Sloan Kettering Cancer Center (3) · National Cancer Institute (NCI) (2) · NYU Langone Health (2) · Verastem, Inc. (1) · SWOG Cancer Research Network (1) · Korea University Anam Hospital (1) · Radboud University Medical Center (1)

Often tested with

Tested in the same studies.

Panitumumab (6) · Trastuzumab deruxtecan (3) · Ladarixin (2) · RO5126766 (1) · Defactinib (1) · Vociprotafib (1) · Batoprotafib (1) · Pan-KRAS Inhibitor BI 1701963 (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Sotorasib is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 9, 1 in phase 3

Studies that test sotorasib, phase 3 first.

Studies

Open first, then newest update. How each study uses sotorasib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 50

See all 50 studies that test sotorasib →

Given beside what is tested · 11 — sotorasib is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with sotorasib

Codes

What other systems call sotorasib · ClinicalTrials.gg INT001295

  • MeSH (NLM) C000706028sotorasibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 2B2VM6UC8GSOTORASIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2550714One source FDA
  • Wikidata Q75175937sotorasibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C154287SotorasibOne source FDA
  • DrugBank DB15569One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.